KRAS and non-small cell lung carcinoma: Furthermore, K-RAS mutations in NSCLC were shown to be synthetic lethal alongside CDK4 inhibition [38] and the CDK inhibitor abemaciclib showed antitumor activity in patients with K-RAS-mutant NSCLCs [39].